Kazia Therapeutics Ltd (ASX: KZA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Kazia Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$36.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
139.33 million
Earnings per share
-0.111
Dividend per share
N/A
Year To Date Return
-80.08%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Kazia Therapeutics Ltd (ASX: KZA)
Latest News

Share Fallers
This ASX healthcare share just crashed 49%, here’s why

Healthcare Shares
3 ASX healthcare shares with big news coming

Healthcare Shares
Here’s why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today

Healthcare Shares
Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today

Share Market News
Kazia (ASX:KZA) share price slides despite positive update

Share Market News
Why the Kazia Therapeutics (ASX:KZA) share price is rocketing 11%

Share Market News
Why Kazia Therapeutics share price has skyrocketed today

Share Market News
Kazia Therapeutics share price soars 46% on new drug grant
KZA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Kazia Therapeutics Ltd
Formerly Norvet Limited (NRT), 30/04/1997 ; Novogen Limited (NRT), 28/11/2017
KZA Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Aug 2022 | $0.26 | $0.01 | 4.00% | 1,213,546 | $0.28 | $0.30 | $0.26 |
05 Aug 2022 | $0.25 | $0.02 | 8.51% | 993,124 | $0.24 | $0.27 | $0.24 |
04 Aug 2022 | $0.24 | $-0.01 | -4.08% | 435,568 | $0.25 | $0.25 | $0.23 |
03 Aug 2022 | $0.25 | $0.00 | 0.00% | 246,128 | $0.25 | $0.25 | $0.24 |
02 Aug 2022 | $0.25 | $0.01 | 4.17% | 901,778 | $0.25 | $0.26 | $0.24 |
01 Aug 2022 | $0.24 | $-0.27 | -52.94% | 2,609,438 | $0.35 | $0.35 | $0.23 |
29 Jul 2022 | $0.51 | $0.02 | 4.04% | 32,662 | $0.52 | $0.53 | $0.51 |
28 Jul 2022 | $0.50 | $-0.04 | -7.55% | 247,907 | $0.52 | $0.52 | $0.50 |
27 Jul 2022 | $0.53 | $0.02 | 3.92% | 230,402 | $0.52 | $0.55 | $0.50 |
26 Jul 2022 | $0.51 | $-0.01 | -1.94% | 16,861 | $0.51 | $0.54 | $0.50 |
25 Jul 2022 | $0.52 | $-0.04 | -7.27% | 67,165 | $0.55 | $0.56 | $0.50 |
22 Jul 2022 | $0.55 | $-0.04 | -6.72% | 86,279 | $0.58 | $0.58 | $0.55 |
21 Jul 2022 | $0.60 | $0.05 | 9.17% | 57,682 | $0.57 | $0.60 | $0.56 |
20 Jul 2022 | $0.55 | $0.05 | 10.00% | 72,449 | $0.51 | $0.57 | $0.51 |
19 Jul 2022 | $0.50 | $-0.04 | -7.41% | 324,575 | $0.56 | $0.56 | $0.49 |
18 Jul 2022 | $0.54 | $-0.02 | -3.57% | 148,773 | $0.57 | $0.58 | $0.53 |
15 Jul 2022 | $0.56 | $-0.02 | -3.45% | 122,392 | $0.60 | $0.60 | $0.55 |
14 Jul 2022 | $0.58 | $-0.03 | -4.92% | 120,851 | $0.60 | $0.60 | $0.58 |
13 Jul 2022 | $0.61 | $-0.01 | -1.63% | 57,126 | $0.62 | $0.63 | $0.60 |
12 Jul 2022 | $0.62 | $0.01 | 1.64% | 72,838 | $0.61 | $0.65 | $0.61 |
11 Jul 2022 | $0.61 | $-0.01 | -1.61% | 35,766 | $0.64 | $0.64 | $0.61 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
20 Dec 2021 | Steven Coffey | Buy | 50 | $54,154 |
On-market trade.
|
20 Dec 2021 | Bryce Carmine | Buy | 47 | $50,470 |
On-market trade.
|
16 Dec 2021 | Iain Ross | Buy | 50 | $53,150 |
On-market trade.
|
16 Dec 2021 | James Garner | Buy | 50 | $53,864 |
On-market trade.
|
27 Aug 2021 | James Garner | Buy | 20 | $27,623 |
On-market trade.
|
27 Aug 2021 | Iain Ross | Buy | 25 | $34,250 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Steven Roy Stent Coffey | Non-Executive Director | Nov 2012 |
Mr Coffey is a Chartered Accountant and registered company auditor and has over 35 years experience in the accounting and finance industry. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993. He sits on the board of a number of large private family companies and audits a number of large private companies and not-for-profit entities. He is Chair of Audit, Risk and Governance Committee, Member of Remuneration and Nomination Committee
|
Mr Iain Ross | Non-Executive DirectorNon-Executive Chairman | Jul 2015 |
Mr Ross, based in the UK, is an experienced Director and has served on a number of Australian company boards. He is Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited. He is also a non-executive director of Palla Pharma Limited (ASX:PAL). In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. His track record includes financing transactions having raised in excess of euros 400 million, both publicly and privately, as well as experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim Other current directorships held by him are Silence Therapeutics plc (LSE:SLN), ReNeuron Group plc (LSE:RENE), Palla Pharma Limited (ASX:PAL) and BiVictriX Therapeutics plc (LSE:BVX) Former directorships (last 3 years): Redx Pharma plc (LSE:REDX), Premier Veterinary Group Plc (LSE:PVG), Anatara Lifesciences Limited (ASX:ANR) and e-Therapeutics plc (LSE:ETX). He is a Member of Remuneration and Nomination Committee, Member of Audit, Risk and Governance Committee.
|
Mr Bryce Carmine | Non-Executive Director | Jun 2015 |
Ms Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company's Executive Committee. Mr Carmine previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. During his career with Lilly, Ms Carmine held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. Ms Carmine is currently Chairman and CEO of HaemaLogiX Pty Ltd, a Sydney based privately owned biotech. He is a Member of Audit, Risk and Governance Committee, Chair of Remuneration and Nomination Committee.
|
Dr James Garner | Chief Executive OfficerManaging Director | Feb 2016 |
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. Dr Garner is a physician by training. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.
|
Ms Catherine (Kate) Jane Hill | Company Secretary | Sep 2016 |
-
|
Catherine (Kate) Jane Hill | Company Secretary |
-
|
|
Gabrielle Heaton | Director of Finance and Administration |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 52,263,824 | 40.32% |
Willoughby Capital Pty Ltd <Willoughby Capital A/C> | 15,500,000 | 11.96% |
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 5,951,957 | 4.59% |
Bnp Paribas Noms Pty Ltd <Drp> | 5,342,372 | 4.12% |
Citicorp Nominees Pty Limited | 2,926,720 | 2.26% |
Mna Family Holdings Pty Ltd <Hishenk Pty Ltd Super A/C> | 1,920,000 | 1.48% |
Netwealth Investments Limited <Wrap Services A/C> | 1,384,872 | 1.07% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 1,316,415 | 1.02% |
Hishenk Pty Ltd | 1,295,000 | 1.00% |
Jamplat Pty Ltd | 1,293,334 | 1.00% |
Mr Iain Ross | 1,000,001 | 0.77% |
Mr Peter Alan Luedeke + Mrs Julia Luedeke <Luedeke Retirement Fund A/C> | 650,000 | 0.50% |
Mr Francis Samson | 570,000 | 0.44% |
Mr Tony Mark Eldridge + Mrs Anita Maree Eldridge <Tm & Am Eldridge Super A/C> | 555,000 | 0.43% |
National Nominees Limited | 506,172 | 0.39% |
D & G Brown Investments Pty Limited | 503,589 | 0.39% |
C & L Jackson Investments Pty Ltd <Jackson Family S/Fund A/C> | 479,001 | 0.37% |
Invia Custodian Pty Limited <Gsjbw Managed A/C> | 454,988 | 0.35% |
El Coronado Holdings | 453,164 | 0.35% |
Mr Ross Richard Eddison | 450,000 | 0.35% |